Abstract: Androgen deprivation therapy for prostate cancer was pioneered by Charles Huggins, laureate of the Nobel Prize in Medicine in 1966. The authors tried to understand the scientific context and how previous findings paved Huggins way to his discoveries. With the help of summary or review articles on androgen deprivation therapy, the authors identified key publications and used his Nobel Prize speech as a basis to understand his discoveries. Furthermore, they used a recording of the laboratory-talk interview he gave about his findings to guide them to relevant publications. The authors found that the basis for Huggins' discoveries was the isolation of testosterone in 1935, not long before Huggins' 1941 hallmark publication. Huggins' work follows major experiments in the 19th century in orchiectomy done as a treatment for prostate hypertrophy. Researching the etiology of idiopathic hydrocele, Huggins analyzed the composition of prostate fluid. Further research led to the discovery of the influence of castration, testosterone, and estrogen on acid phosphatase. Recently developed methods facilitated the measurement of the phosphatases. He, therefore, had a biomarker for metastatic prostate cancer to measure treatment response. Very early on, he reported clinical improvements after castration in metastatic patients. Although the effect of orchiectomy on prostate hypertrophy was already known, Huggins was the first to show that testosterone stimulated and estrogen decreased the activity of prostate cancer. Huggins also established phosphatases as a tumor marker to measure disease response.
(© 2023 American Cancer Society.)
References: Walsh PC. How Charles Huggins made his Nobel prize winning discovery-in his own words: an historic audio recording. Prostate. 2012;72(16):1718. doi:10.1002/pros.22524.
Hansson N, Moll F, Schultheiss D, Krischel M. Remembering Charles B. Huggins' Nobel Prize for hormonal treatment of prostatic cancer at its 50th anniversary. Eur Urol. 2016;69(6):971-972. doi:10.1016/j.eururo.2016.01.030.
NobelPrize.org. Award ceremony speech: NobelPrize.org. Accessed August 3, 2023. https://www.nobelprize.org/prizes/medicine/1966/ceremony-speech/.
Huggins C. Endocrine-induced regression of cancers. Nobel lecture; 1966. https://www.nobelprize.org/uploads/2018/06/huggins-lecture.pdf.
Berthold AA, Quiring D. The transplantation of testes. Bull Hist Med. 1944;16(4):399-401.
White JWI. The results of double castration in hypertrophy of the prostate. Ann Surg. 1895;22(1):1-80. doi:10.1097/00000658-189507000-00001.
David K, Dingemanse E, Freud J, Laquer E. Crystalline male hormone from the testes (Testosterone) is more effective than androsterone derived from urine or cholesterin. Hoppe-Seyler's Z Physiol Chem. 1935;233:281-282.
Butenandt A, Hanisch G. Testosterone. The transformation of dehydroandrosterone into androstendiol and testosterone; a method for producing testosterone from cholesterin. Hoppe-Seyler's Z Physiol Chem. 1935;237:89-98.
Ružička L, Wettstein A. Über die kunstliche Herstellung des Testikelhormons Testosteron (Androsten-3-on-17-ol). [Synthesis of the testicular hormone (testosterone)(androstene 3-on-17-ol)]. Helv Chim Acta. 1935;18(1):1264-1275. doi:10.1002/hlca.193501801176.
Gutman AB, Gutman EB. An "acid " phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest. 1938;17(4):473-478. doi:10.1172/jci100974.
Huggins C, Masina MH, Eichelberger L, Wharton JD. Quantitative studies of prostatic secretion: I. Characteristics of the normal secretion; the influence of thyroid, suprarenal, and testis extirpation and androgen substitution on the prostatic output. J Exp Med. 1939;70(6):543-556. doi:10.1084/jem.70.6.543.
Huggins C, Clark PJ. Quantitative studies of prostatic secretion: II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med. 1940;72(6):747-762. doi:10.1084/jem.72.6.747.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293-297. doi:10.1016/s0022-5347(05)64820-3.
Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004.
Huggins C, Scott WW, Hodges CV. Studies on prostatic cancer. III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol. 1941;46(5):997-1006. doi:10.1016/s0022-5347(17)71004-x.
Huggins C, Sommer JL. Quantitative studies of prostatic secretion: III. Simultaneous measurement of size and secretion of the canine prostate and the interaction of androgenic and estrogenic substances thereon. J Exp Med. 1953;97(5):663-680. doi:10.1084/jem.97.5.663.
Nieschlag E, Nieschlag S. Endocrine history: the history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201-R212. doi:10.1530/eje-19-0071.
Nussbaum M. Hoden und Brunstorgane des braunen Landfrosches (Rana fusca). Archiv für die gesamte Physiologie des Menschen und der Tiere. 1909;126(11-12):519-577. doi:10.1007/bf01677713.
Steinach E. Geschlechtstrieb und echt sekundäre Geschlechtsmerkmale als Folge der innersekretorischen Funktion der Keimdrüsen. Deuticke; 1910.
Pézard A. Sur la détermination des caractères sexuels secondaires chez les gallinacés. Compt Rend Acad des Sciences. 1911;153:1027-1032.
Shackley D. A century of prostatic surgery. BJU Int. 1999;83(7):776-782. doi:10.1046/j.1464-410x.1999.00998.x.
White JW. The present position of the surgery of the hypertrophied prostate: abstract of an address delivered before the American Surgical Association. Br Med J. 1893;2(1706):575-578. doi:10.1136/bmj.2.1706.575.
Moore W. The Knife Man: The Extraordinary Life and Times of John Hunter, Father of Modern Surgery. Broadway Books; 2005.
Nicholson TM, Best SL, Ricke EA, Timms BG, Ricke WA. White's operation: the history of 19(th) century attempts to treat prostate disease with castration. Am J Clin Exp Urol. 2022;10(6):462-466.
Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153-179.
Charles B Huggins MD 1901-1997: The University of Chicago Medicine; 1997. Accessed August 3, 2023. https://www.uchicagomedicine.org/forefront/news/charles-b--huggins-md-1901-1997.
Buch I, Buch H. An improved King and Armstrong method for the determination of phosphatase activity in blood serum. Acta Med Scand. 1939;101(2-3):211-236. doi:10.1111/j.0954-6820.1939.tb07785.x.
Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50(5):935-939. doi:10.1016/j.eururo.2006.06.034.
Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126(3):372-375. doi:10.1016/s0022-5347(17)54531-0.
Harris AE, Metzler VM, Lothion-Roy J, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol. 2022;13:1006101. doi:10.3389/fendo.2022.1006101.
Shiota M, Akamatsu S, Tsukahara S, Nagakawa S, Matsumoto T, Eto M. Androgen receptor mutations for precision medicine in prostate cancer. Endocr Relat Cancer. 2022;29(10):R143-R155. doi:10.1530/erc-22-0140.
Arya M, Shergill IS, Grange P, Emberton M. Hormone therapy: a revolution in understanding prostate cancer. Lancet Oncol. 2008;9(11):1112. doi:10.1016/s1470-2045(08)70282-1.
Processing Request
No Comments.